Headlines about Flexion Therapeutics (NASDAQ:FLXN) have trended positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.348621903447 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
FLXN has been the subject of several research analyst reports. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 1st. BidaskClub lowered Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Royal Bank of Canada set a $44.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, October 29th. Wells Fargo & Co set a $39.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Finally, ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Flexion Therapeutics currently has an average rating of “Buy” and a consensus price target of $99.11.
Shares of Flexion Therapeutics (FLXN) traded up $1.00 during trading on Thursday, reaching $24.58. The company had a trading volume of 1,253,400 shares, compared to its average volume of 698,241. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The stock has a market cap of $943.40, a P/E ratio of -7.16 and a beta of 0.91.
WARNING: “Flexion Therapeutics (NASDAQ:FLXN) Given Daily News Impact Rating of 0.25” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://weekherald.com/2018/02/22/favorable-news-coverage-somewhat-unlikely-to-impact-flexion-therapeutics-flxn-stock-price.html.
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.